Vimarsana
Biggest News Aggregation in the World

Page 8 - Clinical Evolution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Evolution Today - Breaking & Trending Today

Pfizer pours $25m into Vedanta's Phase II IBD study - Vimarsana News

Pfizer pours $25m into Vedanta's Phase II IBD study

Pfizer pours $25m into Vedanta's Phase II IBD study The pharma giant has invested in the clinical trial exploring the viability of Vedanta Biosciences’ VE202 inflammatory bowel disease treatment candidate. PureTech Health, a clinical-stage biotherapeutics firm, has announced its Vedanta Biosciences founded entity has landed a $25m (20.6 EUR) investment as part of the Pfizer Breakthrough Growth Initiative (PGBI). Vedanta plans to use the money to fund its Phase II study of VE202 to treat inflammatory bowel disease (IBD), scheduled to launch in 2021. A Vedanta spok...

Grifols to launch trial for potential COVID-19 therapy - Vimarsana News

Grifols to launch trial for potential COVID-19 therapy

Grifols to launch trial for potential COVID-19 therapy The subcutaneously administered immunoglobulin, if successful, would provide rapid immunity against the virus behind the deadly global pandemic. Biopharmaceutical firm Grifols, which specializes in development of therapies harnessing plasma-derived proteins, has announced it is kicking off a clinical trial in Spain to test the viability of a potential COVID-19 treatment. Based on the company’s immunoglobulin Gamunex-C and containing polyclonal antibodies, the drug at the center of the study reportedly has the...

Ampio enrolls patients for inhalable COVID-19 Phase I trial - Vimarsana News

Ampio enrolls patients for inhalable COVID-19 Phase I trial

The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment. Ampio Pharmaceuticals, a company specializing in immunology-based therapies for inflammatory conditions, has announced that its ongoing Phase I clinical trial in the US, exploring inhalation treatment of COVID-19 with Ampion (AP-014), is now 55% enrolled. The trial is looking at the impact of inhaled Ampion treatments in patients suffering respiratory distress as a result of COVID-19 infection. Inhaled Ampion specif...

Florida doctor pleads guilty to clinical trial data fraud - Vimarsana News

Florida doctor pleads guilty to clinical trial data fraud

Florida doctor pleads guilty to clinical trial data fraud A Miami physician has owned up to falsifying research data and patient participation figures for a pediatric asthma trial conducted from 2013 to 2016. Yvelice Villaman Bencosme of Miami, Florida, has entered a guilty plea in US District Court for the Southern District of Florida, in response to one count of conspiracy to commit wire fraud. Bencosme (who served as primary investigator for clinical purportedly conducted at the medical clinic Unlimited Medical Research in Miami) admitted that from approximately...

Repurposing existing drugs accelerates discovery: XenoTech - Vimarsana News

Repurposing existing drugs accelerates discovery: XenoTech

Repurposing existing drugs accelerates discovery: XenoTech Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO. Pharmaceutical companies and their development partners are continually looking for safe, efficient ways to accelerate delivery of therapies to the patients that need them—especially in the face of the COVID-19 pandemic. One appealing path to new treatments is to explore ways to repurpose a drug intended for one indication and repurpose it for another. ...